PTC Therapeutics Inc (PTCT)

13.16
0.09 0.69
NASDAQ : Health Care
Prev Close 13.07
Open 12.90
Day Low/High 12.76 / 13.28
52 Wk Low/High 5.27 / 60.93
Volume 447.08K
Avg Volume 776.40K
Exchange NASDAQ
Shares Outstanding 34.32M
Market Cap 448.54M
EPS -5.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

PTC Therapeutics Announces Third Annual STRIVE Grant Award Program For Duchenne Muscular Dystrophy

PTC Therapeutics Announces Third Annual STRIVE Grant Award Program For Duchenne Muscular Dystrophy

-Grant Proposals from Nonprofit Patient Advocacy Organizations Due May 31, 2017-

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.

PTCT Crosses Above Average Analyst Target

PTCT Crosses Above Average Analyst Target

In recent trading, shares of PTC Therapeutics Inc have crossed above the average analyst 12-month target price of $14.17, changing hands for $14.29/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

PTC Therapeutics Provides Corporate Update And Outlines 2017 Strategic Priorities To Maximize The Global Value Of Translarna™ And Advance Its Innovative Pipeline

PTC Therapeutics Provides Corporate Update And Outlines 2017 Strategic Priorities To Maximize The Global Value Of Translarna™ And Advance Its Innovative Pipeline

- Preliminary 2016 Translarna unaudited net sales of approximately $81M, a 140% increase vs. 2015 -

Notable Thursday Option Activity: PTCT, HAIN, MRTX

Notable Thursday Option Activity: PTCT, HAIN, MRTX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in PTC Therapeutics Inc , where a total of 3,841 contracts have traded so far, representing approximately 384,100 underlying shares. That amounts to about 56.6% of PTCT's average daily trading volume over the past month of 678,305 shares.

Commit To Purchase PTC Therapeutics At $8, Earn 23.8% Using Options

Commit To Purchase PTC Therapeutics At $8, Earn 23.8% Using Options

Investors eyeing a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $11.72/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $8 strike, which has a bid at the time of this writing of $1.90.

PTC Therapeutics Receives France's 2016 Prix Galien For Translarna™

PTC Therapeutics Receives France's 2016 Prix Galien For Translarna™

- Award recognizes scientific innovation of first approved drug for underlying cause of nonsense mutation Duchenne muscular dystrophy -

PTC Therapeutics Duchenne Drug Wins Extended European Approval

PTC Therapeutics Duchenne Drug Wins Extended European Approval

The news that Translarna will remain on the European market for at least five more years sent PTC Therapeutics shares soaring.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Materials, financials, cyclicals and health care names tilt the scale to the bullish side.

Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916

Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916

- Initiated SUNFISH study to evaluate RG7916 in Type 2/3 SMA patients -

RSI Alert: PTC Therapeutics (PTCT) Now Oversold

RSI Alert: PTC Therapeutics (PTCT) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal

PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal

On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.

Commit To Purchase PTC Therapeutics At $5, Earn 22% Using Options

Commit To Purchase PTC Therapeutics At $5, Earn 22% Using Options

Investors considering a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $10.24/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $5 strike, which has a bid at the time of this writing of $1.10.

PTC Therapeutics Recognizes World Duchenne Awareness Day by Announcing Winners of Global Duchenne Muscular Dystrophy Patient Group Awards and Expanding Disease State Awareness Website

PTC Therapeutics Recognizes World Duchenne Awareness Day by Announcing Winners of Global Duchenne Muscular Dystrophy Patient Group Awards and Expanding Disease State Awareness Website

- STRIVE Awards Program Recognizes Excellence and Innovation in the Duchenne Muscular Dystrophy Community -

10 Best-Performing Stocks This Earnings Season

10 Best-Performing Stocks This Earnings Season

Which stocks have had the highest gains following earnings? Bespoke Investment came up with a list of the 40 stocks that had the best performance on their earnings reaction days.

Today's Perilous Reversal Stock: PTC Therapeutics (PTCT)

Today's Perilous Reversal Stock: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "perilous reversal" (up big yesterday but down big today) candidate

Strong On High Volume: PTC Therapeutics (PTCT)

Strong On High Volume: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a strong on high relative volume candidate

TheStreet Quant Rating: D (Sell)